AnaptysBio, Inc. (ANAB) NASDAQ
65.54
+3.41(+5.49%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
65.54
+3.41(+5.49%)
Currency In USD
| Previous Close | 62.13 |
| Open | 64.47 |
| Day High | 65.93 |
| Day Low | 62.72 |
| 52-Week High | 68.39 |
| 52-Week Low | 15.4 |
| Volume | 561,806 |
| Average Volume | 556,743 |
| Market Cap | 1.88B |
| PE | -142.48 |
| EPS | -0.46 |
| Moving Average 50 Days | 56.27 |
| Moving Average 200 Days | 38.03 |
| Change | 3.41 |
Anaptys Announces Participation at Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 05, 2026 9:15 PM GMT
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer o
Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
GlobeNewswire Inc.
Jan 08, 2026 11:00 PM GMT
Trial to resolve all claims in the Anaptys and Tesaro/GSK dispute is scheduled for July 14-17, 2026 SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovativ
Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 06, 2026 9:15 PM GMT
SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer o